The Value of Oncology Therapies and Emerging Access Hurdles: Germany, Canada, and the United States
This article from Lee et al. details an inquiry into recent value paradigm shifts and emerging market access and reimbursement hurdles in oncology in three key countries–Germany, Canada, and the US–and identifies what can be learned from the evolving landscape for developing access strategies and value propositions.
How (Not) To Assess the Social Value of Medical Interventions for Ultra-Rare Disorders (URDs): Recommendations from the URD Evaluation Project
Michael Schlander and colleagues report on an expert consensus recommending that the evaluation of drugs for ultra-rare disorders (URDs) should insist on strong evidence of clinical benefits, whereas meaningful economic analysis may require an entirely new evaluation paradigm, capturing social value beyond the aggregation of individual health gains valued by individual preferences.